Phase II trial of ATx08-001 in patients with postherpetic neuralgia.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs ATx08 001 (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2011 Primary endpoint 'Pain-intensity' has been met.
- 19 Aug 2011 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
- 19 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.